Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908189 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
A Phase 3 study of Psoriatic Arthritis, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- Phase 3
- Development phase
- 729
- Enrollment target
- 20
- Study locations
NCT04908189: Active Phase 3 study of Psoriatic Arthritis, sponsored by Bristol-Myers Squibb.
NCT04908189 is a Phase 3 study of Psoriatic Arthritis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 729 participants, below the 838-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04908189, a Phase 3 study of Psoriatic Arthritis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 729 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.
Primary Outcome
The American College of Rheumatology (ACR) 20 is defined as 20% improvement over baseline in tender (68) and swollen (66) joint counts and a 20% improvement in 3 of the 5 remaining core data set measures: Participant Global Assessment of Disease Activity; Participant Global Assessment of Pain; Participant assessment of physical function; Physician Global Assessment of psoriatic arthritis; and Acute phase reactant value of high sensitivity C-reactive protein (hsCRP). Baseline is defined as the la
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Deucravacitinib
- DRUG Apremilast
Study Locations (20)
California
- Local Institution - 0212 - Sacramento
- Local Institution - 0188 - Whittier
New York
- Local Institution - 0108 - New York
- Local Institution - 0186 - Rochester
Texas
- Local Institution - 0167 - Lubbock
- Local Institution - 0070 - Mesquite
Alabama
- Local Institution - 0149 - Mountain Brook
Illinois
- Local Institution - 0192 - Skokie
Kentucky
- Local Institution - 0203 - Hopkinsville
Louisiana
- Local Institution - 0195 - Baton Rouge
Maryland
- Local Institution - 0169 - Cumberland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 729 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2026-11-12 |
| Phase | Phase 3 |
What the registry record for NCT04908189 still lists
NCT04908189 is an interventional study that assigns participants to a tested intervention. The registered 729 participants enrollment target is mid-sized for trials with a published cap, below the 838-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04908189 names 20 study sites across 17 states, led by California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04908189 about?
NCT04908189 is a clinical study titled "A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment". The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will...
What is the current status of trial NCT04908189?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 729 participants. The study started on 2021-07-15. Estimated completion is 2026-11-12.
What conditions does trial NCT04908189 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT04908189?
The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG), Apremilast (DRUG).
Who is sponsoring clinical trial NCT04908189?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04908189 being conducted?
This trial has 20 study locations across Alabama, California, Illinois, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04908189's enrollment target sits among peer trials
729 10th of 48 higher than 39 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT07312162 · 730 participants
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI